Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt falls 5.3% from a year ago

Net debt stood at $140.02M at the end of Q1 FY2026, down 5.3% from a year earlier and down 19.1% from the prior quarter. Over 3 fiscal years it compounded at +58.0% a year.

Context

  • Net debt amounted to 106.5% of total assets at the end of Q1 FY2026, down 9.3 pp from a year earlier.
  • Net debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -5.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$140.02M-19.1% QoQ
Last fiscal yearDec 2025
$173.07M+31.1% YoY
Year agoMar 2025
$147.92M-5.3% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.3%——
1 year+31.1%——
3-year CAGR+58.0%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
173.07M USD
Year-over-year change
+31.1%

Net Debt vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's Mar 2026 net debt of $140.02M is the highest of the 4 companies compared; the peer median is -$19.85M.
  • Its year-over-year change of -5.3% is the 2nd highest of 4, against a peer median of -469.6%.
  • Net debt amounts to 106.5% of total assets for KPTI, versus a peer median of 76.9%.
KPTI Competitors Peer median
Net Debt for KPTI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KPTIKaryopharm Therapeutics Inc.Mar 2026$140.02M -5.3%+58.0%106.5%
TELOTelomir Pharmaceuticals, Inc. Common StockMar 2026-$5.36M -1630.7%—92.5%
INMBINmune Bio, Inc.Mar 2026-$19.85M -4.5%—76.9%
XFORX4 Pharmaceuticals, Inc.Mar 2026-$139.66M -469.6%—51.7%
Peer median (excluding KPTI) -$19.85M-469.6%—76.9%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents190.46M135.19M52.23M62.48M60.54M
Short-term Investments38.16M142.78M139.21M46.24M3.2M
Net Receivables22.5M47.09M26.96M30.77M26.18M
Inventory4.11M4.22M3.04M4.74M4.04M
Other Current Assets6.35M20.89M12.47M12.28M9.19M
Total Current Assets275.61M350.16M233.92M156.49M103.15M
Property, Plant & Equipment (Net)9.56M7.38M4.88M6.28M4.65M
Goodwill00000
Intangible Assets00000
Long-term Investments0000351K
Tax Assets00000
Other Non-current Assets20.14M633K1.64M1.64M267K
Total Non-current Assets29.7M8.01M6.52M7.93M5.27M
Total Assets305.31M358.17M240.44M164.42M108.42M
Account Payables1.6M2.77M3.12M5.11M4M
Short-term Debt00024.43M21.01M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities20.37M21.47M18.16M15.56M5.96M
Total Current Liabilities73.72M65.91M69.48M92.26M92.06M
Long-term Debt169.29M170.11M170.92M162.95M205.89M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000072.34M
Other Non-current Liabilities133M132.72M133.46M88.51M25.32M
Total Non-current Liabilities311.26M308.92M307.17M258.17M309.28M
Total Liabilities384.98M374.83M376.64M350.44M401.34M
Common Stock8K12K12K13K14K
Retained Earnings(1.18B)(1.34B)(1.49B)(1.56B)(1.76B)
Accumulated OCI191K(638K)(161K)(356K)71K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(79.67M)(16.66M)(136.21M)(186.02M)(292.93M)
Total Debt180.58M179.07M177.02M194.52M233.61M
Net Debt(9.88M)43.89M124.79M132.05M173.07M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.